Innate Pharma S.A. Board of Directors

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Mr. Jonathan E. Dickinson

Mr. Jonathan E. Dickinson

Chairman of the Executive Board & CEO

Mr. Eric Vivier D.V.M., M.B.A., Ph.D.

Mr. Eric Vivier D.V.M., M.B.A., Ph.D.

Founder, Senior VP & Chief Scientific Officer

Mr. Yannis Morel Ph.D.

Mr. Yannis Morel Ph.D.

Executive VP, COO & Member of Executive Board

Mr. Arvind Sood

Mr. Arvind Sood

Executive VP, President of US Operations & Member of Executive Board

Dr. Sonia Quaratino M.D., Ph.D.

Dr. Sonia Quaratino M.D., Ph.D.

Executive VP, Chief Medical Officer & Member of Executive Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.